WALTHAM, Mass.--(BUSINESS WIRE)--May 9, 2006--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI - News) today reported financial results for the first quarter ended March 31, 2006. During the first quarter of 2006, the Company recorded total revenues of $11.0 million, compared with $3.9 million in total revenues for the first quarter of 2005. In the first quarter of 2006, $9.2 million in revenue was generated from the Company's lead product, FACTIVE® (gemifloxacin mesylate) tablets, FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis (AECB) and mild to moderate community-acquired pneumonia (CAP). Oscient also recorded approximately $1.5 million in revenue from the Company's co-promotion agreement with Auxilium Pharmaceuticals for TESTIM® 1% testosterone gel.
